Chitosan Plus Compound 48/80: Formulation and Preliminary Evaluation as a Hepatitis B Vaccine Adjuvant
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Chitosan Plus Compound 48/80: Formulation and Preliminary Evaluation as a Hepatitis B Vaccine Adjuvant
Authors
Keywords
-
Journal
Pharmaceutics
Volume 11, Issue 2, Pages 72
Publisher
MDPI AG
Online
2019-02-12
DOI
10.3390/pharmaceutics11020072
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Virus-Like Particle, Liposome, and Polymeric Particle-Based Vaccines against HIV-1
- (2018) Yong Gao et al. Frontiers in Immunology
- Mechanistic study of the adjuvant effect of chitosan-aluminum nanoparticles
- (2018) F. Lebre et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- Unimpaired Responses to Vaccination With Protein Antigen Plus Adjuvant in Mice With Kit-Independent Mast Cell Deficiency
- (2018) Nadja Schubert et al. Frontiers in Immunology
- Association of chitosan and aluminium as a new adjuvant strategy for improved vaccination
- (2017) F. Lebre et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- Adjuvant Activity of Poly-ε-caprolactone/Chitosan Nanoparticles Characterized by Mast Cell Activation and IFN-γ and IL-17 Production
- (2017) Sandra Jesus et al. MOLECULAR PHARMACEUTICS
- Poly-ϵ-caprolactone/chitosan nanoparticles provide strong adjuvant effect for hepatitis B antigen
- (2017) Sandra Jesus et al. Nanomedicine
- Immune response elicited by an intranasally delivered HBsAg low-dose adsorbed to poly-ε-caprolactone based nanoparticles
- (2016) Sandra Jesus et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- Intranasal Administration of Novel Chitosan Nanoparticle/DNA Complexes Induces Antibody Response to Hepatitis B Surface Antigen in Mice
- (2016) F. Lebre et al. MOLECULAR PHARMACEUTICS
- Development of a novel adjuvanted nasal vaccine: C48/80 associated with chitosan nanoparticles as a path to enhance mucosal immunity
- (2015) D. Bento et al. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
- Validation of a New 96-Well Plate Spectrophotometric Method for the Quantification of Compound 48/80 Associated with Particles
- (2013) Dulce Bento et al. AAPS PHARMSCITECH
- ATR-FTIR spectroscopy as a tool to probe surface adsorption on nanoparticles at the liquid–solid interface in environmentally and biologically relevant media
- (2013) Imali A. Mudunkotuwa et al. ANALYST
- Chitosan nanoparticles: Preparation, size evolution and stability
- (2013) Antonio Rampino et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- Nanoparticle vaccines
- (2013) Liang Zhao et al. VACCINE
- The effect of antigen encapsulation in chitosan particles on uptake, activation and presentation by antigen presenting cells
- (2012) Bhanuprasanth Koppolu et al. BIOMATERIALS
- Nanogel vaccines targeting dendritic cells: Contributions of the surface decoration and vaccine cargo on cell targeting and activation
- (2012) L.J. Thomann-Harwood et al. JOURNAL OF CONTROLLED RELEASE
- Surface Charge Affects Cellular Uptake and Intracellular Trafficking of Chitosan-Based Nanoparticles
- (2011) Zhan-Guo Yue et al. BIOMACROMOLECULES
- Intracellular degradation and distribution of protein-encapsulated amphiphilic poly(amino acid) nanoparticles
- (2011) Takami Akagi et al. BIOMATERIALS
- Particulate vaccines: on the quest for optimal delivery and immune response
- (2011) Marie-Luce De Temmerman et al. DRUG DISCOVERY TODAY
- Trends in vaccine adjuvants
- (2011) Virgil EJC Schijns et al. Expert Review of Vaccines
- Stable Dry Powder Formulation for Nasal Delivery of Anthrax Vaccine
- (2011) Sheena H. Wang et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Mucosal Targeting of a BoNT/A Subunit Vaccine Adjuvanted with a Mast Cell Activator Enhances Induction of BoNT/A Neutralizing Antibodies in Rabbits
- (2011) Herman F. Staats et al. PLoS One
- Bioadhesive chitosan nanoparticles: Preparation and characterization
- (2010) Anitha R. Dudhani et al. CARBOHYDRATE POLYMERS
- Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses
- (2010) Moses O Oyewumi et al. Expert Review of Vaccines
- Combination adjuvants: the next generation of adjuvants?
- (2010) George Mutwiri et al. Expert Review of Vaccines
- Towards preserving the immunogenicity of protein antigens carried by nanoparticles while avoiding the cold chain
- (2010) Brian R. Sloat et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- Chitosan-based delivery systems for protein therapeutics and antigens
- (2009) Maryam Amidi et al. ADVANCED DRUG DELIVERY REVIEWS
- Biodegradation, biodistribution and toxicity of chitosan
- (2009) T. Kean et al. ADVANCED DRUG DELIVERY REVIEWS
- Chitosan-based systems for the delivery of vaccine antigens
- (2009) H. Çiğdem Arca et al. Expert Review of Vaccines
- The safety of chitosan as a pharmaceutical excipient
- (2009) Paul Baldrick REGULATORY TOXICOLOGY AND PHARMACOLOGY
- The mast cell activator compound 48/80 is safe and effective when used as an adjuvant for intradermal immunization with Bacillus anthracis protective antigen
- (2009) Afton L. McGowen et al. VACCINE
- Mast cell activators: a new class of highly effective vaccine adjuvants
- (2008) James B McLachlan et al. NATURE MEDICINE
- New horizons in adjuvants for vaccine development
- (2008) Steven G. Reed et al. TRENDS IN IMMUNOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started